Peptide · Research peptide

TB-500

Research peptide

Aliases · Thymosin Beta-4 fragment · TB4 · Thymosin beta-4 fragment

TB-500 is an investigational peptide, analogue or research construct with evidence ranging from mechanistic studies to limited human trials.

Human

0/5

Animal

0/5

In-vitro

0/5

Safety

0/5

Last reviewed · 7/12/2026

Compare with another peptide →

Last reviewed7/12/2026

Evidence statusEvidence in progress

Published references1

Trust signal panel

Evidence & safety

Human evidence
n/a
Animal evidence
n/a
Mechanistic
n/a
Safety knowledge
n/a
Editorial confidence
3/5

View in knowledge graph →See this peptide connected to conditions & mechanisms

Evidence Snapshot

Evidence snapshot · 0 verified refs

Overall: 0/5None identified
Human: 0/5None identified
Animal: 0/5None identified
In-vitro: 0/5None identified
Safety: 0/5None identified

Scientific identity

Peptide family: Investigational peptide or analogue
Entity class: Research peptide
Alternative names: Thymosin Beta-4 fragmentTB4Thymosin beta-4 fragment

Discovery history

TB-500 entered research, clinical or commercial use through investigation of its proposed biological, cosmetic or therapeutic activity.

Proposed Mechanisms

Actin sequestration / cytoskeletal remodelling
in-vitro
Angiogenesis promotion
preclinical
Anti-inflammatory signalling
preclinical
Actin cytoskeleton and cell migration →
supported
Wound repair →
supported

Reported / Studied Uses

Tendon and ligament repair
Evidence · animal
Soft-tissue recovery
Evidence · animal + anecdotal
Tendon Healing / Tendinopathy
Evidence · insufficient
Ligament Healing
Evidence · needs review
Back Pain
Evidence · needs review
Neck Pain
Evidence · needs review
Muscle Strain
Evidence · needs review
Rotator Cuff Injury
Evidence · needs review
Sports Injury
Evidence · needs review
Wound Healing / Tissue Repair
Evidence · insufficient

Human Evidence

Human evidence is absent, limited, early phase or indication-specific.

Animal Evidence

Animal evidence may support biological activity but does not establish clinical efficacy.

Species translation to humans is uncertain.

Safety & Unknowns

investigationallimited-human-evidenceno-established-general-use

Long-term safety, validated dosing and product quality may be uncertain outside formal clinical development.

Regulatory Status

Country	Status	Notes
World Anti-Doping Agency	Prohibited	Listed as a prohibited substance in sport.
United Kingdom	Not authorised as a medicine	Sold as research chemical only.
United States	Not FDA-approved	Compounding restricted.

Community Observations

No approved community reports yet. Submit one. Aggregate data is observational only.

References

[1]Sikiric 2018 BPC-157 review

Full Disclaimer

This page is for educational information only. It does not constitute medical advice, diagnosis, treatment, dosing guidance, or a recommendation to use any peptide, medicine or research chemical. Many peptides discussed on Atlas are not approved for human use in most jurisdictions and may have limited or unknown long-term safety data.

Community observations shown on this page are anonymised, moderated and observational only. They do not establish safety or effectiveness.

Always consult a qualified healthcare professional before making decisions about your health. See medical disclaimer and methodology.

↳

Explore further

from the knowledge graph

Mechanisms

Conditions

Related peptides

Sources cited

Sikiric 2018 BPC-157 review

Advertise here — support independent evidence →